Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns.
Maier
S
S
Oncology Medical Strategy, Bristol-Myers Squibb, Plainsboro, NJ. Electronic address: sabine.maier@bms.com.
Peltz
G
G
Global Health Outcomes-Oncology, Eli Lilly and Company, Indianapolis, IN.
Penrod
J R
JR
Oncology Health Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ.
Sugarman
K P
KP
Oncology Business Unit, Eli Lilly and Company, Indianapolis, IN, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003628:Database Management Systems; D006801:Humans; D007345:Insurance Claim Review; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab